Building a Foundation: What You Need to Know About CAD
At a Glance
Cold Agglutinin Disease (CAD) is a rare autoimmune disorder where the immune system destroys red blood cells in cool temperatures. While chronic, it is highly manageable with cold avoidance and targeted therapies. In emergencies, CAD patients must only receive warmed IV fluids and blood.
Being diagnosed with a rare condition can feel overwhelming, especially when you may be the only person your local doctor has ever seen with it. Cold Agglutinin Disease (CAD) is a very rare form of autoimmune hemolytic anemia—a condition where your immune system mistakenly attacks and destroys its own red blood cells [1][2].
If it took months or even years for you to get this diagnosis, you are not alone. Because the condition is so rare, many patients endure a frustrating “diagnostic odyssey” before finding answers. While it is a chronic, lifelong condition, it is manageable with modern therapies and lifestyle adjustments.
Understanding Your Diagnosis
In a healthy body, the immune system produces antibodies to fight infections. In CAD, the body produces a specific type of autoantibody called monoclonal IgM [1][3]. These antibodies have a unique “personality”: they become active and “sticky” at colder temperatures [4].
When your blood travels to the cooler parts of your body—like your fingers, toes, nose, or ears—these IgM antibodies attach to your red blood cells. This triggers a part of your immune system called the classical complement pathway [2][1]. This pathway marks the red blood cells for destruction, primarily in the liver, leading to hemolysis (the breaking open of red blood cells) [5][6].
Is it “Primary” or “Secondary”?
Your doctors will work to determine which type of the disease you have (read more in Primary CAD vs. Secondary CAS: Finding the Root Cause):
- Primary CAD: This is considered a distinct, slow-growing disorder of the bone marrow [7][8]. It is not a typical cancer, but rather a “clonal” condition where a specific group of B-cells produces the troublesome antibodies [3].
- Secondary Cold Agglutinin Syndrome (CAS): This is a temporary or “secondary” reaction caused by something else, such as a recent viral infection (like the flu or COVID-19) or another underlying medical condition [1][9].
Facts to Steady You
It is natural to feel a sense of panic after receiving a rare diagnosis. Here are three stabilizing facts to help you gain your footing:
- You are not alone, even though it is rare: CAD affects approximately 1 in 100,000 people globally [10]. While your local clinic may not see it often, there is a dedicated international community of experts and researchers focused entirely on this condition.
- It is highly manageable: While there is currently no “cure” for primary CAD, it is a chronic condition that can be managed effectively [11]. Many patients live full lives by combining “cold avoidance” strategies with modern medical treatments.
- Treatment has evolved rapidly: For years, the only options were keeping warm or using older chemotherapies. Today, there are targeted therapies, such as complement inhibitors (like sutimlimab), that can stop the destruction of red blood cells quickly and significantly improve energy levels [12][13].
What to Expect
The course of CAD is typically chronic and may include “flares” during winter months or during infections [4]. The most common symptoms include profound fatigue, acrocyanosis (blue or purple discoloration of the hands and feet), and an increased risk of blood clots. You can learn more about managing these in Living with the Chill: Symptoms, Triggers, and Daily Life.
You will also need to monitor your bloodwork regularly. Understanding your lab results is crucial; learn how in The Science of the Squeeze: Understanding Your Labs and Biology.
Finally, as you build your care plan, explore your options in Navigating Your Options: Treatments for CAD.
Emergency Medical Alert Guide
Since many local emergency rooms may not be familiar with CAD, it is highly recommended to keep these rules handy or print them on a medical alert card to hand to nurses and doctors:
- NO COLD FLUIDS: All intravenous (IV) fluids must be warmed before administration.
- NO COLD BLOOD: Any blood transfusions must use a continuous inline blood warmer [1][14].
- WARM ROOM: Keep the patient in a warm room and provide heated blankets immediately.
In this guide
4 chapters
Living with the Chill: Symptoms, Triggers, and Daily Life
Learn about Cold Agglutinin Disease (CAD) symptoms and triggers. Understand thermal amplitude, hemolysis signs, and daily tips for managing cold avoidance.
The Science of the Squeeze: Understanding Your Labs and Biology
Learn how to read your Cold Agglutinin Disease (CAD) lab reports. Understand IgM antibodies, DAT results, and why pre-warming your blood sample is critical.
Primary CAD vs. Secondary CAS: Finding the Root Cause
Learn the difference between Primary Cold Agglutinin Disease (CAD) and Secondary Syndrome (CAS). Understand causes, biopsy results, and treatment options.
Navigating Your Options: Treatments for CAD
Learn about Cold Agglutinin Disease (CAD) treatment options. Understand supportive care, B-cell therapies like rituximab, and fast-acting complement inhibitors.
Common questions in this guide
What is the difference between primary CAD and secondary CAS?
What should I tell the emergency room if I have CAD?
Why do my hands and feet turn blue in the cold?
Can cold agglutinin disease be cured?
How do doctors treat cold agglutinin disease?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.What is my current cold agglutinin titer, and at what 'thermal amplitude' (temperature range) do my antibodies become active?
- 2.Based on my tests, do I have 'primary' Cold Agglutinin Disease or 'secondary' Cold Agglutinin Syndrome caused by another condition?
- 3.Has a bone marrow biopsy or flow cytometry been performed to check for the underlying B-cell clone that characterizes this disease?
- 4.What is my risk for blood clots (thromboembolism), and should we consider preventative measures?
- 5.Are there specific complement-targeted therapies, like sutimlimab, or B-cell therapies, like rituximab, that are appropriate for my case?
- 6.What are the 'red flag' symptoms that should prompt me to seek immediate medical attention during a cold-induced flare?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
References
References (14)
- 1
Complement-mediated hemolysis persists year round in patients with cold agglutinin disease.
Röth A, Fryzek J, Jiang X, et al.
Transfusion 2022; (62(1)):51-59 doi:10.1111/trf.16745.
PMID: 34813663 - 2
Increased risk of thrombotic events in cold agglutinin disease: A 10-year retrospective analysis.
Broome CM, Cunningham JM, Mullins M, et al.
Research and practice in thrombosis and haemostasis 2020; (4(4)):628-635 doi:10.1002/rth2.12333.
PMID: 32548562 - 3
Cold agglutinin disease: where do we stand, and where are we going?
Berentsen S, Malecka A, Randen U, Tjønnfjord GE
Clinical advances in hematology & oncology : H&O 2020; (18(1)):35-44.
PMID: 32511221 - 4
Short course of bortezomib in anemic patients with relapsed cold agglutinin disease: a phase 2 prospective GIMEMA study.
Rossi G, Gramegna D, Paoloni F, et al.
Blood 2018; (132(5)):547-550 doi:10.1182/blood-2018-03-835413.
PMID: 29898955 - 5
A middle-aged woman with the initial symptom of acrocyanosis diagnosed with cold agglutinin disease: A case report.
Salimi B, Salimi M, Tavakoli Avval M, et al.
SAGE open medical case reports 2025; (13()):2050313X251342166 doi:10.1177/2050313X251342166.
PMID: 40386534 - 6
A case of autoimmune hemolytic anemia with cold agglutinin disease post-operation for recurrent ovarian cancer.
Sugimoto A, Yamada H, Tasaki K, et al.
International cancer conference journal 2025; (14(3)):235-240 doi:10.1007/s13691-025-00758-x.
PMID: 40625772 - 7
Diagnosis and management of cold agglutinin disease.
Berentsen S
Hematology. American Society of Hematology. Education Program 2025; (2025(1)):295-304 doi:10.1182/hematology.2025000718.
PMID: 41348049 - 8
Cold agglutinin syndrome secondary to splenic marginal zone lymphoma: a case report.
Portich JP, Blos B, Sekine L, Franz JPM
Hematology, transfusion and cell therapy 2023; (45(3)):403-405 doi:10.1016/j.htct.2021.07.009.
PMID: 34836848 - 9
[Cold agglutinin syndrome associated with infectious mononucleosis: A case report].
Garzón-Recalde DA, Rentería-Castillo E, Anda-Garay JC
Revista medica del Instituto Mexicano del Seguro Social 2024; (62(1)):1-7.
PMID: 39116196 - 10
Prevalence and incidence of primary autoimmune hemolytic anemia and cold agglutinin disease in the United States, 2016-2023.
Bozzi S, Umarje S, Hawaldar K, et al.
PloS one 2025; (20(6)):e0323843 doi:10.1371/journal.pone.0323843.
PMID: 40570006 - 11
Occurrence, thromboembolic risk, and mortality in Danish patients with cold agglutinin disease.
Bylsma LC, Gulbech Ording A, Rosenthal A, et al.
Blood advances 2019; (3(20)):2980-2985 doi:10.1182/bloodadvances.2019000476.
PMID: 31648316 - 12
Sutimlimab in Cold Agglutinin Disease.
Röth A, Barcellini W, D'Sa S, et al.
The New England journal of medicine 2021; (384(14)):1323-1334 doi:10.1056/NEJMoa2027760.
PMID: 33826820 - 13
Sutimlimab for the Treatment of Cold Agglutinin Disease.
Berentsen S
HemaSphere 2023; (7(5)):e879 doi:10.1097/HS9.0000000000000879.
PMID: 37153870 - 14
Cold agglutinin-induced hemolytic anemia during room temperature fluid resuscitation: a case report.
Kawai Y, Deguchi M, Mizouchi N, et al.
Journal of medical case reports 2021; (15(1)):169 doi:10.1186/s13256-021-02784-8.
PMID: 33858500
This page provides educational information about Cold Agglutinin Disease for patients and caregivers. It does not replace professional medical advice, diagnosis, or treatment planning from your hematologist or healthcare team.
Get notified when new evidence is published on Autoimmune hemolytic anemia, cold type.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.